Kent Lake Urges Quanterix (NASDAQ: QTRX) Shareholders to Reject Akoya Merger, Citing Value Destruction and Governance Concerns

Kent Lake Partners, a 7.7% shareholder of Quanterix, urges fellow shareholders to vote AGAINST the proposed merger with Akoya Biosciences, calling it a value-destructive deal that unjustly benefits Akoya at Quanterix shareholders’ expense. The firm highlights that the merger would slash Quanterix’s net cash per share by nearly 60%, introduce significant financial risk, and result in Quanterix issuing shares at a negative enterprise value to acquire a heavily indebted company. Kent Lake criticizes the flawed deal process, citing governance conflicts, unrealistic projections, and Akoya’s financial distress—including covenant violations and going-concern doubts. It also points to superior standalone alternatives for Quanterix, given its strong balance sheet, proprietary Simoa platform, and opportunities in Alzheimer’s diagnostics. Kent Lake asserts the board failed to act in shareholders’ best interests and calls on investors to reject the merger and preserve long-term value.